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Seroepidemiology of Plasmodium 
species infections in Zimbabwean population
Seth A. Amanfo1*, Takafira Mduluza2,3, Nicholas Midzi4, David R. Cavanagh1 and Francisca Mutapi1
Abstract 
Background: Individuals living in malaria-endemic regions may be exposed to more than one Plasmodium species; 
there is paucity of data on the distribution of the different species of Plasmodium in affected populations, in part due 
to the diagnostic method of microscopy, which cannot easily differentiate between the species. Sero-epidemiological 
data can overcome some of the shortcomings of microscopy.
Methods: The specificity of IgG antibodies to recombinant merozoite surface protein 1 (MSP-119) derived from four 
human Plasmodium species (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale) was 
investigated using competition enzyme-linked immunosorbent assay. Subsequently, these antigens were used to 
determine the exposure prevalence to the different Plasmodium species in serum samples of participants. One-hun-
dred individuals, aged five-18 years, from each of the three Plasmodium meso-endemic Zimbabwean villages (Burma 
Valley, Mutoko, Chiredzi) were recruited in the study.
Results: The study demonstrated that the host serum reactivity to MSP-119 antigens was species-specific and that no 
cross-reactivity occurred. The overall prevalence of antibody response to MSP-119 antigens was 61 % in Burma Valley, 
31 % in Mutoko and 32 % in Chiredzi. Single species IgG responses to MSP-119 were most frequent against P. falcipa-
rum, followed by P. malariae and P. ovale, with responses to P. vivax being the least prevalent. Interestingly, 78–87 and 
50 % of sera with IgG responses to P. malariae and P. ovale MSP-119, respectively, also had IgG specific response for P. 
falciparum MSP-119 antigens, indicating that exposure to these species is a common occurrence in these populations. 
Single species IgG responses to the non-falciparum species were at a very low frequency, ranging between 0 and 
13 % for P. malariae.
Conclusions: There is evidence of a higher exposure to the non-falciparum parasite species than previously reported 
in Zimbabwe. The recombinant MSP-119 antigens could be used as additional diagnostic tools in antibody assays for 
the detection of exposure to the different Plasmodium species. The results also introduce an interesting concept of 
the co-infection of non-falciparum Plasmodium almost always with P. falciparum, which requires further validation and 
mechanistic studies.
Keywords: Antibody, Merozoite surface protein 1 (MSP-119), Plasmodium, Microscopy
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is a major public health problem in sub-Saharan 
Africa, and is responsible for over half a million deaths 
annually, especially in children under the age of 5  years 
[1]. Four major species of the protozoan parasite, Plas-
modium, (Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae, Plasmodium ovale) cause human 
malaria in sub-Saharan Africa. In malaria-endemic coun-
tries, there is an overlap in the geographic distribution 
of the different Plasmodium species and the Anoph-
eles mosquito vectors that transmit these parasites, and 
that individuals may be exposed to, and harbour multi-
ple Plasmodium species [2]. However, the epidemiology 
of the different Plasmodium species in endemic human 
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populations is not well documented [3]. Diagnosis of 
malaria in endemic clinical settings is predominantly by 
the ‘gold standard’ blood film microscopic examination, 
and rapid diagnostic tests (RDT), both of which lack 
sensitivity in differentiating the species of Plasmodium 
causing malaria. Microscopic examination has several 
limitations such as the inability to detect low levels of 
parasitaemia, and the difficulty in species differentiation 
owing to subtle differences in the morphology of blood 
stage parasites [4]. This results in the species of Plasmo-
dium causing disease being rarely reported, and almost 
all cases of malaria are therefore attributed to P. falcipa-
rum, the species causing the most serious form of malaria 
[3]. This has led to underestimates of the prevalence of 
both mixed-species and non-falciparum species infec-
tions [5]. These non-falciparum species are of significant 
clinical importance; for example, P. vivax and P. ovale 
which form latent liver stage ‘hypnozoites’ are capable of 
causing disease several months or years after the primary 
infection [6]. Incidences of the diagnosis of systemic dis-
eases caused by P. malariae several months or years after 
people have returned from malaria-endemic regions have 
been reported [7]. In some cases, drug treatment failure 
attributable to the misdiagnosis of primary infections 
caused by the non-falciparum species or as co-infecting 
species with P. falciparum have been observed [8]. While 
PCR typing of infecting Plasmodium species is not fre-
quently available or applicable in many African field set-
tings, most RDTs may not differentiate non-falciparum 
species [3]. There is an urgent need for additional diag-
nostic tools [2–4] capable of rapid detection of all four 
infecting Plasmodium species for effective treatment and 
control of malaria.
In this study, a new assay has been developed that 
detects exposure to all four human Plasmodium spe-
cies based on serum antibody responses to merozoite 
surface protein 1 (MSP-1). The surface of the invasive 
merozoite is coated in MSP-1 that constitutes 31 % of the 
GPI-anchored proteins on P. falciparum merozoites [9]. 
MSP-1 is expressed by all four human Plasmodium spe-
cies. In P. falciparum, MSP-1 undergoes two proteolytic 
cleavages resulting in a C-terminal MSP-119 fragment 
that is carried into the erythrocyte during merozoite 
invasion [10, 11]. Until recently, only the MSP-1 genes 
of P. falciparum and P. vivax had been characterized. 
Recently, the sequences of the MSP-119 gene fragments 
for P. malariae and P. ovale have been determined with 
limited characterization of the responses to these para-
site proteins [12]. Although the gene sequences of MSP-
119 antigens are unique to each of these four Plasmodium 
species, extensive homology can be found among them. 
The number and relative positions of cysteine resi-
dues within the C-terminus fragments of MSP-119 are 
comparable in all four Plasmodium species [12]. For 
example, there are about 32 amino acid sites within the 
MSP-119 gene where all four parasite species share the 
same amino acid, and about 30 sites where the same 
amino acid is conserved in two or three species (Addi-
tional file 1: Figure S1). To date, there has been no field 
study using MSP-119 antigens from all four malaria para-
site species to characterize the epidemiology of exposure 
to Plasmodium in any African population.
In Zimbabwe over half of the population are exposed to 
malaria, with P. falciparum being the predominant spe-
cies, accounting for almost all cases of the disease [13]. 
There is little epidemiological data of exposure to non-
falciparum species and/or mixed Plasmodium infections 
in Zimbabwe. The aim of this study is to determine the 
species specificity of IgG antibody responses to recom-
binant Plasmodium MSP-119 antigens in three meso-
endemic villages of Zimbabwe: Burma Valley, Mutoko 
and Chiredzi. Using these antigens as diagnostic tools, 
this study describes the sero-epidemiology of multiple 
Plasmodium species infections in these study sites.
Methods
Study sites and population
Serum samples were collected in three Zimbabwean vil-
lages where malaria parasite transmission is described as 
meso-endemic [13], as part of studies investigating the 
immuno-epidemiology of schistosomiasis in villages with 
Plasmodium co-infection. The study sites were Burma 
Valley in the northeast, where samples were collected in 
1994, Chiredzi in the southeast where samples were col-
lected in 1999 and Mutoko in central Zimbabwe, where 
samples were collected in 2003. The study cohort con-
sisted of 100 participants aged between 5 and 18  years 
(both males and females) in each study site (Table  1). 
Antibody responses to merozoite surface proteins were 
detected using enzyme-linked immunosorbent assays 
(ELISA).
Ethical approval and consent
The studies in the different study sites received ethical 
approval from the Medical Research Council of Zimba-
bwe. Permission to conduct the work in each of the three 
Table 1 Summary of study population
100 individuals from each village were recruited into the study
Study area Age range  
(years)
Median age 
(years)
Sex
Male  
(%)
Female 
(%)
Burma valley 6–15 10 49 51
Mutoko 5–18 9.5 36 64
Chiredzi 7–16 11 52 48
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villages was obtained from the Provincial Medical Direc-
tor, the District Educational Officer and Heads of schools 
in the study sites. Project aims and procedures were fully 
explained to the study participants and/or their guardian. 
Informed oral consent/assent was obtained from parents/
guardians, or participants if older than 10 years, prior to 
enrolment of the participants into the study. The partici-
pants were recruited into the study on a voluntary basis 
and were free to withdraw with no further obligation.
Recombinant antigens
MSP-1 antigens used in the ELISAs were expressed in 
Escherichia coli transformed with pGEX-derived plas-
mid constructs [14–17] as recombinant proteins fused to 
glutathione S-transferase (GST). These were purified by 
affinity chromatography using HiTrap glutathione Sepha-
rose columns on an AKTAprime system and quantified 
by the Bradford protein assay.
Serology
Sera were tested by ELISA for the presence of IgG 
antibodies able to recognize the recombinant mero-
zoite surface proteins as an indication of recent or cur-
rent exposure; 96-well plates (Immulon4 HBX; Dynex, 
Greiner Microlon) were coated with 100  μL of 0.5  μg/
mL of recombinant antigen in carbonate bicarbonate 
buffer (15  mM Na2CO3, 35  mM NaHCO3, pH 9.4) and 
incubated overnight at 4 °C in a humidified atmosphere. 
Plates were washed four times in washing buffer (0.05 % 
Tween-20 in PBS) using Skatron Skanwasher to remove 
unbound antigens and blotted on paper towels (Kimber-
ley Clark 3-ply hand towels Cat No. 6771). Free binding 
sites in wells were blocked with 200 μL per well of block-
ing buffer (1  % (w/v) skimmed milk powder in the PBS 
buffer) for 5 h at room temperature and then plates fur-
ther washed four times. Human serum diluted 1:500 in 
the blocking buffer (100 μL per well) was added in dupli-
cate to the Ag-coated wells and incubated overnight at 
4 °C. After four washes, the wells were incubated for 3 h 
at room temperature with 100  μL per well of horserad-
ish peroxidase-conjugated rabbit antihuman IgG (1:5000) 
(Dako Ltd, High Wycombe, UK). Plates were washed four 
times to remove unbound secondary antibody before 
reaction development with 100  μL of substrate buffer 
[(0.04  mg/mL of o-phenylenediamine; Sigma, St Louis, 
MO, USA; 0.012 % H2O2 in development buffer (24.5 mM 
citric acid monohydrate and 52 mM Na2HPO4, pH 5.0)] 
for 10–15 min at room temperature. An unstopped posi-
tive control plate was read at an optical density (OD) 
450 nm, with an OD 450 nm of 0.7–0.8 taken to be equiv-
alent to OD 492 nm of 2.5–3.0. The reaction was stopped 
by the addition of 25 μL of 2 M H2SO4 per well, and OD 
was measured at 492 nm (Labsystems Multiskan Ascent 
microtitre plate reader). GST protein, purified from 
Escherichia coli transfected with pGEX-2T alone, was 
used as a control to determine the non-specific (back-
ground) binding of human IgG to the GST. Corrected 
OD values for each plasma sample were calculated by 
subtracting the mean OD value of wells containing con-
trol GST protein from the mean OD value obtained with 
each test MSP-1 antigen. Cut-off values at which binding 
of Ab from malaria-exposed individuals was regarded as 
significantly above background were calculated as cor-
rected OD above the mean plus 4 standard deviation 
of OD readings obtained with sera from eight Scottish 
blood donors with no history of exposure to malaria. 
The same positive controls (pooled sera from Brefet, The 
Gambia) were run in duplicate, on each plate, to allow for 
standardization of plate-to-plate variations.
Competition ELISA
Competition ELISA was performed for individuals with 
substantial antibody reactivity to more than one MSP-
119 antigen, to assess whether human anti-MSP-119 IgG 
antibodies specific for MSP-119 were species-specific or 
cross-reacted with each other. Serum was pre-incubated 
with different concentrations of MSP-119 antigen, and 
then added to the wells of microtitre plates coated with 
either the homologous or heterologous MSP-119 antigen. 
The rationale of the competition ELISA is that appropri-
ate antigen epitopes will react with their corresponding 
paratopes in the sera, so that with increasing antigen 
concentration, all paratopes in the sera react with the 
antigen, leaving none available to bind to antigen on the 
plate [18]. In the case of antigens without correspond-
ing paratopes in the sera, there will be no prior reactiv-
ity between the serum and antigens, regardless of the 
antigen concentration. The same ELISA protocol above 
was followed with slight modification. Plates were coated 
with recombinant MSP-119 Ag and incubated overnight 
at 4  °C. Serum was diluted (1:500) and pre-incubated 
with increasing concentrations (0–10  μg/mL) of soluble 
competing homologous or heterologous Ag, i.e., with up 
to 20-fold excess over the 0.50  μg/mL immobilized Ag 
to allow sera to bind to the antigen before reacting with 
the antigen bound on the plate, then tested on the plate-
bound Ag overnight. This was followed by washing and 
incubation with a horseradish peroxidase-conjugated 
second Ab, as described above.
Statistical analyses
To determine if exposure prevalence derived from single 
species data differed from that based on multiple species, 
Chi square (χ2) tests were used.
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Results
Specificity of Plasmodium MSP‑119 antigens
Competition ELISA showed that in sera reactive 
against recombinant MSP-119 antigens from more 
than one parasite species, anti-MSP-119 IgG antibody 
responses were species-specific and did not cross-react. 
As a positive control, when P. falciparum MSP-119 anti-
gen was coated onto microtitre plates (as capture Ag), 
sera pre-incubated with P. falciparum MSP-119 (com-
peting homologous Ag), were inhibited from binding 
in a dose-dependent manner (Fig.  1). This inhibition 
occurred at competing homologous Ag concentration 
as low as 0.1  μg/mL. Similar results were observed 
when the homologous competitor Ags were either P. 
malariae or P. ovale MSP-119. To assess anti-MSP-119 
cross-reactivity, P. falciparum MSP-119 antigen was 
coated onto microtitre plates and dual specificity sera 
were pre-incubated with increasing concentrations of 
the heterologous P. malariae or P. ovale MSP-119 anti-
gens. IgG binding to P. falciparum MSP-119 antigen 
was not inhibited by soluble heterologous P. malariae 
or P. ovale MSP-119, even at concentration 20 times 
the capture antigen. This was also true when the coat-
ing and competing antigens were reversed in the assay 
(Fig. 1).
Prevalence of human IgG antibodies to recombinant 
MSP‑119 antigens from four Plasmodium species
Antibody recognition of the panel of four Plasmodium 
recombinant MSP-119 antigens was tested by ELISA 
against 100 sera from each of the three study sites (Burma 
Valley, Mutoko, Chiredzi). The observed overall preva-
lence of IgG response to all recombinant MSP-119 anti-
gens was 61, 31 and 32  % in the Burma Valley, Mutoko 
and Chiredzi villages, respectively (Table 2). There were 
no significant differences between the exposure preva-
lence between the villages (Burma Valley vs Mutoko: 
χ2 = 0.002, df = 1, P = 0.97), (Burma Valley vs Chiredzi: 
χ2 = 0.423, df = 1, P = 0.52) and (Mutoko vs Chiredzi: 
χ2 = 0.001, df = 1, P = 0.97).
Fig. 1 Competition ELISA showing species specificity of Abs to recombinant Plasmodium MSP-119 antigens for individuals 1 and 2. Sera were 
tested at 1:500 dilution. Legends indicate the pairs of competing antigens used, with the well-bound capture antigen listed first and the competing 
homologous or heterologous antigen second. The capture antigens were coated at 50 ng/well. The x-axis indicates increasing concentrations of 
competing antigen added to the diluted sera
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Single vs multiple Plasmodium species anti‑MSP‑119 
responses
Of the individuals with anti-MSP-119 responses in 
all three study areas, Burma Valley (n  =  61), Mutoko 
(n = 31) and Chiredzi (n = 32), single species responses 
were the most common occurrence, and these were pre-
dominantly directed against P. falciparum MSP-119 anti-
gens (80, 68.8 and 78.3 %, respectively), with responses to 
P. malariae or P. ovale ranging from 0 to 31.2 % (Table 2). 
The proportion of individuals with single versus multiple 
species anti-MSP-119 responses in all three study villages 
were comparable.
In responders with antibodies to multiple Plasmo-
dium species, antibody responses to the non-falciparum 
species were almost always accompanied by responses 
against P. falciparum MSP-119 antigens in all three study 
areas. Multiple responses to P. falciparum- and P. malar-
iae MSP-119 were the most common, with about 78–87 
and 50  % of all sera with IgG responses to P. malariae 
and P. ovale MSP-119, respectively, also having IgG-spe-
cific response for P. falciparum MSP-119 antigens. The 
high exposure prevalence of IgG responses to P. malariae 
MSP-119 antigens suggests that infection with this para-
site species is at a higher frequency in these populations 
than has been previously reported, and are predomi-
nantly co-responses to the main response to P. falcipa-
rum MSP-119 antigen.
While there were no single species responders to P. 
malariae MSP-119 in Mutoko, a much higher propor-
tion (31.2  %) responded to three parasite antigens (P. 
malariae, P. falciparum, P. ovale) compared to the other 
two villages. Only one individual in Chiredzi had an 
antibody response to P. vivax antigen in addition to a 
response to P. falciparum (Table 2). When single species 
responses involving only P. falciparum was compared to 
multiple species responses involving P. falciparum with 
P. malariae and/or P. ovale, no significant difference was 
observed in all three villages (Fig. 2).
When the cohort was divided into two age groups, 
based on the median ages (i.e., those below 10 years and 
those 10 years and above), it was observed that the over-
all exposure prevalence in the two age groups were com-
parable in both Burma Valley (χ2 = 3.5, df = 1, P = 0.06) 
and Mutoko (χ2 =  0.05, df =  1, P =  0.83). However, in 
Chiredzi a significantly higher exposure prevalence 
was observed in responders aged 10  years and above 
compared to those below 10  years (χ2  =  6.13, df  =  1, 
P  =  0.01) (Table  3). Differences between the two age 
groups in responders to single and multiple species in 
all three study areas were not compared because of the 
smaller sample sizes involved.
Discussion
In this current study, IgG responses to recombinant 
MSP-119 antigens (an indication of prior exposure to 
Plasmodium antigens) from the four major human 
Plasmodium species were evaluated in three Zimba-
bwean villages with meso-endemic malaria transmission 
dynamics. Individuals living in malaria-endemic regions 
may harbour multiple Plasmodium species owing to the 
Fig. 2 Prevalence of single Plasmodium falciparum vs multiple species anti-MSP-119 responses. Observed prevalence of single spp. P. falciparum 
anti-MSP-119 responses were compared with multiple responses involving P. falciparum with P. malariae and/or P. ovale in all three study sites
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geographical overlap of the four major human Plasmo-
dium species [4, 19, 20]. Malaria diagnosis in most Afri-
can field settings is largely by microscopy of blood films, 
which reports the presence or absence of Plasmodium 
parasites without cognisance to the species causing dis-
ease. Low-level parasitaemia of the non-falciparum spe-
cies in mixed infection with P. falciparum accounts for 
the misdiagnosis of these species. There have been case 
study reports of treatment failures [21] and acute renal 
injury [22] attributable to undiagnosed P. malariae infec-
tion or co-infection. Knowledge of the type of infecting 
species is therefore essential for effective treatment as 
well as the implementation of control programmes. IgG 
responses to P. falciparum MSP-119 antigens have been 
shown to rise following clinical episodes of malaria and 
decline in the absence of the disease [15]. In the cur-
rent study, the antibody response to Plasmodium species 
recombinant MSP-119 antigens in humans was seen to be 
highly species-specific. Furthermore, the study showed 
that the responses were not cross-reactive, despite the 
amino acid sequence similarities between the four Plas-
modium MSP-119 antigens. In experimental monkey 
and human studies utilizing all four Plasmodium species 
MSP-119 antigens, a superior sensitivity was seen when 
compared to commercially available antibody assays 
which only utilize MSP-119 antigens from P. falciparum 
and P. vivax and depend on cross-reactivity in detecting 
the other two species [23]. The specificity of antibodies to 
these antigens supports the evidence that these antigens 
could be used in pan-malaria diagnostic assay to enable 
the rapid detection of the type of Plasmodium species 
causing malaria [23].
In many malaria-endemic countries in sub-Saharan 
Africa, P. falciparum is the predominant species that 
causes malaria, thus it was not surprising that the anti-
body response to P. falciparum MSP-119 antigens was 
predominant in all three study sites. Since P. falcipa-
rum infections have higher parasitaemias than the other 
malaria parasite species [20, 24], it is likely that individu-
als will have a stronger immune response to P. falcipa-
rum infection. The novel results from this study were the 
indication that the exposure prevalence of P. malariae 
and P. ovale is higher, as previous reports have attributed 
about 98  % of malaria in Zimbabwe to be caused by P. 
falciparum. More importantly, the observed higher expo-
sure prevalence of P. malariae in the Burma Valley dis-
trict was striking, as reports suggest that this species only 
accounts for between 1 and 2.6 % of all malaria cases by 
light microscopy [25–27].
Microscopy has long been known to underestimate 
the prevalence of the non-falciparum species owing to 
difficulties in distinguishing the subtle differences in the 
morphology of the different species as well as the chal-
lenge posed in detecting minority species in a blood 
film with high density P. falciparum parasitaemia. It 
is therefore not surprising that these assays detected 
a higher sero-prevalence of these species, as this also 
reflects recent and concurrent parasite exposure. Studies 
employing nucleic acid based techniques for Plasmodium 
parasite detection and species identification in some 
African countries have reported prevalence of the non-
falciparum species to be between 1 and 17 % [20, 24].
While antibody responses to single species P. falcipa-
rum antigens were common, single species responses 
to P. malariae and P. ovale antigens were infrequently 
detected. A significant proportion of individuals with 
IgG responses to P. malariae and/or P. ovale MSP-119 
almost always had responses to P. falciparum MSP-119. 
This results support the findings of a recent study in 
Ghana, which reported frequent detection of P. malar-
iae and P. ovale in individuals who are also PCR positive 
for P. falciparum [28]. The reasons for this co-occur-
rence of the non-falciparum species with P. falciparum 
may be both epidemiological and biological. Of the 
epidemiological reasons, it has been suggested that the 
same Anopheles mosquito circulating in a population 
might be responsible for the simultaneous or sequential 
inoculation of the different species [4], thereby increas-
ing the likelihood of multiple species infections. Biolog-
ical reasons may include selective advantages for these 
minor species when co-infecting with P. falciparum. 
For example, due to density-dependent regulation of 
immune responses directed against the majority spe-
cies (P. falciparum), these non-falciparum species may 
be able to evade host immune responses and establish 
disease [29, 30]. There are parallels in other infectious 
diseases, such as the obligate satellite virus hepatitis 
D, which is unable to establish disease independent of 
hepatitis B virus [31]. Hepatitis D virus co-infection 
in Hepatitis B-infected individuals worsens hepatic 
damage and inflammation, and is more likely to lead 
to hepatocellular carcinoma [32, 33]. The results show 
some single species P. malariae responses, indicat-
ing that this species is capable of establishing infection 
independent of other Plasmodium. However, the sig-
nificant proportion of individuals with co-occurrence 
of antibody responses to P. falciparum suggests a pos-
sible dependency on P. falciparum receptors or proteins 
for successful disease by P. malariae. These non-falci-
parum species, which usually exist as part of a complex 
mixed-infections with P. falciparum [2, 34] may cause 
chronic, sub-clinical disease with potential health con-
sequences, including treatment failure, disease relapse 
and long-term systemic consequences [5–7]. A recent 
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study in Indonesia found P. malariae to be associated 
with a lower mean haemoglobin, nephrotic syndrome 
and death [27].
Antibody responses to P. vivax MSP-119 were rarely 
observed in this study. Plasmodium vivax requires the 
Duffy antigen to establish a successful infection [35], and 
is predominantly endemic in Asian and Latin American 
countries. It has long been known that the Duffy anti-
gen is absent in most African populations [35]; it was 
therefore not surprising to observe a low frequency of 
responses to P. vivax MSP-119. In recent years however, 
there have been reports of P. vivax infections in both 
Duffy positive and negative individuals in Cameroon 
[36] suggesting that this species might have evolved and 
adapted to using other receptors to invade erythrocytes 
and establish disease.
Serological responses generally increase with age. In 
this present study, age was not a confounding factor in 
Burma Valley and Mutoko, while is Chiredzi respond-
ers 10 years old and above had a higher overall exposure 
prevalence to parasite antigens. Although all three vil-
lages are described as meso-endemic, the observed dif-
ferences in age responses could be due to the respective 
transmission dynamics of the different seasons in which 
sampling was done. In very low and unstable malaria 
transmission areas such as Daraweesh in eastern Sudan, 
reports suggest that the age dynamics associated with 
malaria and serological responses are not apparent, as 
malaria affects all age groups [37, 38].
Conclusions
This study has shown for the first time that IgG antibod-
ies to recombinant MSP-119 antigens of the four major 
human Plasmodium species are species-specific. The 
study also demonstrates that in Zimbabwean popula-
tions exposed to Plasmodium infections, the prevalence 
of the non-falciparum species responses is higher than 
previously reported in many other cross-sectional studies 
(reviewed in [3]). Finally, the study has demonstrated that 
a high proportion of individuals with antibody responses 
to non-falciparum MSP-119 antigens also had antibodies 
to P. falciparum MSP-119. MSP-119 antigens from all four 
major species of human malaria parasite offer a poten-
tial diagnostic tool for the rapid detection of exposure 
to multiple Plasmodium species such as in blood trans-
fusion screening services. It remains to be established if 
these exposure responses to multiple Plasmodium spe-
cies indicated by the serological survey correspond to 
concurrent or sequential exposure to previous or current 
infections.
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